Gilead CEO Sells Shares Worth 2 Billion Won, Retains Approximately 500,000 Shares

On January 28, 2026, Gilead Sciences, Inc. (Nasdaq: GILD) Chairman and CEO Daniel O’Day sold 10,000 shares of the company’s common stock on the open market under a pre-established Rule 10b5-1 trading plan. The shares were sold at an average price of approximately $140 per share, generating total proceeds of about $1.4 million (roughly 2 billion KRW). After the sale, O’Day continues to hold approximately 550,000 shares of Gilead common stock.

Earlier, on January 15, Chief Operating Officer Johanna Mercier and Chief Financial Officer Andrew Dickinson each sold roughly 3,000 shares under their own 10b5-1 plans at about $124 per share, securing around $370,000 (approximately 500 million KRW) apiece. Both executives remain significant shareholders, each holding several hundred thousand shares.

Gilead’s stock has been on a five-day winning streak, closing up more than 2% at $140.97 on January 27—its highest level in 52 weeks. The company has scheduled its fourth-quarter and full-year 2025 financial results for release after market close on February 10, 2026. On the same day, Gilead’s management team will host a webcast to discuss the results and provide a business update.

Headquartered in Foster City, California, Gilead Sciences is a biopharmaceutical company specializing in treatments for serious illnesses, including HIV, hepatitis B and C, COVID-19, and various cancers. Its products are distributed in over 35 countries worldwide. Daniel O’Day has served as Gilead’s CEO and Board Chair since March 2019. Prior to joining Gilead, he was a leader in Roche’s pharmaceutical division and is recognized as a veteran of the global biopharma industry.